Work

Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM).

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.2575

Authors: Stergios J. Moschos, Shahneen Kaur Sandhu, Karl D. Lewis, Ryan J. Sullivan, Douglas Buckner Johnson, Yilong Zhang, Erik Rasmussen, Haby A. Henary, Georgina V. Long

Institutions: University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Peter MacCallum Cancer Centre, University of Colorado Denver, Massachusetts General Hospital, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Amgen (United States), The University of Sydney, Melanoma Institute Australia

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2776946053

Cites:

Cited by: 12

Related to: 10